VCEL Q3 2021 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena

VCELVericel Corporation

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$35M+7.0% YoY

Gross Profit

$22M64.0% margin

Operating Income

-$5M-14.4% margin

Net Income

-$5M-14.3% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

-12.7%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$1M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$224M

Total Liabilities

$67M

Stockholders' Equity

$157M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35M	$32M	+7.0%
Gross Profit	$22M	$22M	-1.7%
Operating Income	-$5M	$4M	-241.1%
Net Income	-$5M	$4M	-236.3%

Revenue Segments

MACI Implants and Kits, and Epicel

$34M100%